Competition Pharmaceutical manufacturing Safety 
European Pharmaceutical Review
DECEMBER 4, 2023
To address these issues, companies should adopt more advanced production strategies such as continuous flow chemistry, as they can shorten manufacturing processes, increase productivity and throughput. Simultaneously, there is increasing need for stringent quality control and traceability throughout the supply chain to ensure patient safety.
PM360
JANUARY 24, 2025
Brand managers use GVD assets across multiple regulatory and strategic deliverables, including data summaries for efficacy, safety, and cost-effectiveness that feed health technology assessments. SLRs aim to answer specific questions related to drug safety, efficacy, and comparative effectiveness, often contributing to GVDs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
APRIL 11, 2024
Globally, the pharmaceutical sector emitted around 52 megatonnes of CO 2 in 2015, the most recent period for which detailed numbers are available. 1 Every major pharmaceutical manufacturer in the UK and Ireland is investing in making their operations and supply chains more environmentally friendly.
Impetus Digital
AUGUST 2, 2024
Manufacturing Optimization While the manufacturing industry lags behind others in terms of AI uptake, there is no shortage of potential ways to leverage this technology. Regulatory Compliance Regulatory frameworks are continuously evolving in the pharmaceutical industry.
pharmaphorum
NOVEMBER 25, 2022
Having a healthy and sustainable pharmaceutical sector is both a necessary requirement and a good one for society. Going beyond the standards of care; improving drug safety and efficacy. What the Chiesi Group is doing is making people safe and people’s safety comes first in any system, he said.
European Pharmaceutical Review
NOVEMBER 8, 2022
Pharmaceutical manufacturers have submitted Citizen Petitions raising safety or efficacy concerns about proposed competing generic and biosimilar products, and such submissions often delay FDA approval of the proposed products while the FDA resolves the pending petitions.
Pharmaceutical Technology
NOVEMBER 25, 2022
For pharmaceutical manufacturers and contract manufacturing organizations (CMOs) with containment capabilities, this likely means a distinct advantage over those without. Dedicated manufacturers are investing heavily in these services, powered by client requirements.
Expert insights. Personalized for you.
105 
Let's personalize your content